Plain-English translation of NCT07351487 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for triple-negative breast cancer that includes chemotherapy along with two immunotherapy medications: Sintilimab and Bevacizumab. You would receive this combination before surgery to try to shrink the tumor, then have surgery, and then continue with additional treatment based on how your tumor responds. The goal is to see if this approach helps more patients achieve complete remission.
Triple-negative breast cancer is an aggressive form that doesn't respond to many standard treatments, and patients need better options. This study is exploring whether combining chemotherapy with immunotherapy medications can improve how well the treatment works and help patients live longer.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of chemotherapy combined with the two immunotherapy medications every 3 weeks for 12 weeks before your surgery. After your surgery, depending on how well the tumor responds, you would either continue with immunotherapy alone or receive additional chemotherapy combined with immunotherapy for up to a year. Throughout the study, you will have blood tests, imaging scans, and tissue samples collected to monitor your progress.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China